Novo Nordisk and Lilly can't keep up with demand for their weight loss drugs such as Ozempic, Wegovy and Mounjaro. But they object to specialty pharmacies making their own cheaper versions to fill the gap — providing as much as 30% of those drugs sold in the U.S.
